Last updated: February 16, 2026
Summary
NDC 75834-0325 refers to Lenvatinib mesylate, marketed as Lenvima. It is an oral tyrosine kinase inhibitor approved for multiple cancer indications, including differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma. As of 2023, Lenvatinib has a competitive position in the oncology space, with demand driven by expanding indications and ongoing off-label use. Pricing remains within high-cost oncology drug ranges, with US prices averaging approximately $13,000–$14,000 per month. Market dynamics are influenced by generic competition, regulatory approvals, and payer policies.
Market Landscape
Indications and Market Penetration
- Approved Indications:
- Differentiated thyroid carcinoma (2015)
- Hepatocellular carcinoma (2018)
- Renal cell carcinoma (2018)
- Other exploratory uses in endometrial carcinoma, lung cancer
Competitive Environment
- Lenvatinib faces competition from drugs such as sorafenib (Nexavar), cabozantinib (Cabometyx), and emerging immunotherapies.
- The entry of generics is limited; patent expiry is expected around 2035, with some patent extensions possible.
Market Size and Revenue Estimates (2022-2023)
| Metric |
Data |
Notes |
| Global oncology drug market size |
~$182 billion (2022) |
Expected growth at approximately 6% CAGR through 2027 |
| Lenvatinib's share |
Estimated $1.2 billion (2022) |
Primarily driven by US and Japan |
| US market revenue |
~$800 million (2022) |
Reflects high reimbursement coverage |
| Market growth rate |
10-12% annually |
Driven by new approvals and expanding indications |
Usage Patterns
- Predominantly administered in outpatient settings.
- Administered daily, with continuous treatment cycles.
- Patient adherence influenced by side effect profile, including hypertension and gastrointestinal symptoms.
Price Projections
Current Pricing Benchmarks
- Average wholesale price (AWP): $13,000–$14,000 per month (per standard package of 4 mg capsules).
- Average sale price (ASP): Approximately 15-20% discount from AWP.
- Medicaid and Medicare pricing: Negotiated rates often lower; typical discounts range from 10% to 25%.
Future Price Trends
- Patent expiry and generic entry: Anticipated around 2035, which may reduce prices by 30-50% based on historical reductions post-generic launches in oncology.
- Market competition: Increased competition around 2028-2030 could put downward pressure on pricing.
- Regulatory and policy influences: Price negotiations and value-based pricing agreements may further constrain list prices.
Projected Price Decay Scenarios
| Scenario |
Year |
Monthly Price |
Comments |
| Conservative |
2023–2027 |
$13,000 |
Stable prices with limited OTC alternatives |
| Moderate decline |
2028–2032 |
$9,000 |
Entry of generics; pricing adjusts accordingly |
| Aggressive decline |
2033+ |
$6,500 |
Post-patent expiry; generic dominance |
Key Drivers of Market and Pricing Changes
- Regulatory approvals expanding to new tumor types can stimulate sales.
- Patent litigation may delay generics, maintaining higher prices longer.
- Healthcare policy shifts towards cost containment and value-based pricing.
- Emerging biosimilars or novel therapies could erode Lenvatinib’s market share.
Implications for Stakeholders
- Pharmaceutical companies should monitor patent statuses, and consider life-cycle management strategies or indications expansion.
- Payers and providers need to negotiate value-based contracts to manage costs.
- Investors should watch regulatory and patent landscapes to gauge future revenue potential.
Summary Tables
Price Comparison with Similar Oncology Drugs
| Drug |
Typical Monthly Price |
Indications |
Patent Status |
| Lenvatinib |
$13,000–$14,000 |
Thyroid, liver, kidney cancers |
Patent until ~2035 |
| Sorafenib |
$12,500 |
Liver, kidney, thyroid |
Patent expired in 2014 |
| Cabozantinib |
$12,800 |
Kidney, breast, thyroid |
Patent until 2030 |
Market Entry and Expansion Timeline
| Year |
Event |
| 2023 |
Stable pricing, ongoing indications expansion |
| 2025 |
Potential trial results for additional indications |
| 2028 |
Entry of the first generics (predicted) |
| 2035 |
Patent expiry, generic competition increases |
Key Takeaways
- Lenvatinib remains a high-price oncology agent with stable revenue in the near term.
- Market expansion through new indications supports growth; patent expiry looming around 2035.
- Price reduction post-generic entry could be significant, affecting revenue streams.
- Competitive landscape is intensifying with newer therapies and biosimilars, which could alter demand.
- Regulatory trends towards value-based pricing may impact future list prices.
Frequently Asked Questions
1. What is the current market size for Lenvatinib?
Estimates indicate $1.2 billion globally in 2022, with US sales around $800 million.
2. When are generic versions expected to enter the market?
Around 2035, if patent protections are not extended or litigated.
3. How does Lenvatinib price compare with similar drugs?
It is priced similarly to other TKIs like cabozantinib and sorafenib, within $12,500–$14,000 per month.
4. What factors could influence future prices?
Patent expiration, competition from generics or biosimilars, regulatory changes, and healthcare policy shifts.
5. What are the opportunities for growth?
Indication expansion, inclusion in combination therapies, and potential approvals in new tumor types.
References
- IQVIA Institute for Human Data Science. (2022). Global Oncology Market Report
- FDA. (2023). Lenvatinib (Lenvima) approval history and indications
- MarketWatch. (2023). Oncology drug pricing trends
- MedPage Today. (2022). Impact of biosimilars on cancer therapy prices
- EvaluatePharma. (2023). Pharmaceutical sales database
